A new daily weight-loss pill called orforglipron outperformed oral semaglutide in a major phase 3 trial, delivering better blood sugar control and greater weight loss in people with type 2 diabetes. Meanwhile, rival drug elecoglipron also showed strong phase 2 results. The oral GLP-1 market is rapidly expanding, with multiple pill-form options potentially on the horizon — no injections or refrigeration required.
The injectable GLP-1 era may be giving way to a pill-powered future. Orforglipron (Foundayo, Eli Lilly), already FDA-approved for weight management, has now proven superior to oral semaglutide in a 52-week phase 3 trial (ACHIEVE-3) involving nearly 1,700 adults with type 2 diabetes. It beat oral semaglutide on both blood sugar control and weight loss — without the fasting restrictions that come with semaglutide pills. Separate ACHIEVE trials also showed orforglipron outperformed dapagliflozin and worked well as an add-on to insulin glargine.
Hot on its heels is elecoglipron (AstraZeneca), a similar small-molecule oral GLP-1 that showed promising phase 2 results in both the SOLSTICE (type 2 diabetes) and VISTA (obesity) trials. Up to 10.5% body weight loss was seen at 26 weeks in the obesity trial, with weight still falling at 36 weeks. AstraZeneca is now advancing it to phase 3. A third contender, CX11 (CORXEL Pharmaceuticals), also hit its phase 2 endpoints with up to 11.5% weight loss and a favorable safety profile.
By the Numbers
Why it matters: These drugs don't require injections, refrigeration, or fasting — making them far easier to use and distribute globally, especially in low- and middle-income countries. With multiple oral GLP-1s in the pipeline, patients and clinicians may soon have a robust menu of affordable, accessible options for managing obesity and type 2 diabetes.
